Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients - 21/11/24
, P. Hernandez 2, K. Liow 3, E. Damiano 1, H. Zetterberg 4, 5, K. Blennow 4, 5, D. Feng 6, M. Chen 6, M. Maccecchini 1
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Background |
Previously we reported the clinical safety and pharmacological activity of buntanetap (known as Posiphen or ANVS401) in healthy volunteers and mild cognitive impaired (MCI) patients (21). The data supported continued clinical evaluation of buntanetap for treating Alzheimer’s Disease (AD). Neurodegenerative diseases such as AD and Parkinson’s disease (PD) share several pathological manifestations, including increased levels of multiple neurotoxic protein aggregates. Therefore, a treatment strategy that targets toxic species common to both disorders can potentially provide better clinical outcomes than attacking one neurotoxic protein alone. To test this hypothesis, we recently completed a clinical study in early AD and early PD participants and report the data here.
Objectives |
We evaluated safety, pharmacokinetics, biomarkers, and efficacy of buntanetap in treating early AD and PD patients.
Design |
Double-blind, placebo-controlled, multi-center study.
Setting |
13 sites in the US participated in this clinical trial. The registration number is NCT04524351 at ClinicalTrials.gov.
Participants |
14 early AD patients and 54 early PD patients.
Intervention |
AD patients were given either 80mg buntanetap or placebo QD. PD patients were given 5mg, 10mg, 20mg, 40mg, 80mg buntanetap or placebo QD.
Measurements |
Primary endpoint is safety and tolerability; secondary endpoint is pharmacokinetics of buntanetap in plasma; exploratory endpoints are 1) biomarkers in cerebrospinal fluid (CSF) in both AD and PD patients 2) psychometric tests specific for AD (ADAS-Cogs & WAIS coding test) or PD (MDS-UPDRS & WAIS coding test).
Results |
Buntanetap was safe and well tolerated. Biomarker data indicated a trend in lowering levels of neurotoxic proteins and inflammatory factors and improving axonal integrity and synaptic function in both AD and PD cohorts. Psychometric tests showed statistically significant improvements in ADAS-Cog11 and WAIS coding in AD patients and MDS-UPDRS and WAIS coding in PD patients.
Conclusions |
Buntanetap is well tolerated and safe at doses up to 80mg QD in both AD and PD patients. Cmax and AUC increase with dose without evidence for a plateau up to 80mg QD. The drug shows promising evidence in exploratory biomarker and efficacy measures. Further evaluation of buntanetap in larger, longer-term clinical trials for the treatment of AD and PD are warranted.
El texto completo de este artículo está disponible en PDF.Key words : Alzheimer’s disease (AD), Parkinson’s disease (PD), neurotoxic aggregating proteins, iron response element (IRE), iron regulatory protein (IRP)
Esquema
| Conflict of interest Cheng Fang, Eve Damiano & Maria Maccecchini are employed by Annovis Bio. Priscilla Hernandez & Kore Liow received funding from Annovis Bio for the conduct of the clinical trial, Henrik Zetterberg and Kaj Blennow received funding from Annovis Bio for biomarker analysis and Michael Chen and David Feng received funding from Annovis Bio for statistical analysis. |
Vol 10 - N° 1
P. 25-33 - janvier 2023 Regresar al número
Artículo precedente
- ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan
- Eric Siemers, J. Hitchcock, K. Sundell, R. Dean, J. Jerecic, E. Cline, K. Iverson, J. Moore, C. Edgar, R. Manber, N. Fuin, T. Poppe, R. Barton
- US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging
- Chelsea G. Cox, M.A. Davis, J.D. Grill, J.S. Roberts
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.